Position in PCRX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$560,118
-$1,649,529 QoQ
Shares Held
22,078
-77.4% QoQ
Ownership
0.055%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#118
of 253 holders
Holding Since
Jun 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PCRX Over Time
Shares Held
Position Value (USD)
Derivatives in PCRX
reported options exposure · as of Mar 31, 2025CallValue
$3,024,245
CallShares
121,700
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026J. Goldman & Co LP holds $3,690,441 across 4 Drug Manufacturers - Specialty & Generic names. PCRX ranks #3 (15.2% of the industry book) .
All Filings in PCRX
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $560,118 | 22,078 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $2,209,647 | 97,772 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $11,316,107 | 437,253 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $17,243,737 | 669,140 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $15,691,879 | 656,564 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $3,024,245 | 121,700 | Call | Sole | 2025-05-15 | |
| 2025-03-31 | $21,349,405 | 859,131 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $2,543,400 | 135,000 | Call | Sole | 2025-02-14 | |
| 2024-12-31 | $2,395,374 | 127,143 | Shares | Sole | 2025-02-14 | |
| 2023-06-30 | $2,700,718 | 67,400 | Call | Sole | 2023-08-14 | |
| 2023-06-30 | $2,080,875 | 51,931 | Shares | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||